MONTREAL, QUEBEC--(Marketwired - May 1, 2014) - Pediapharm Inc. (“Pediapharm” or the “Corporation”) (TSX VENTURE:PDP) is pleased to announce that it has engaged Paradox Public Relations Inc. (“Paradox”) as strategic investor relations consultants to the Corporation. Paradox will focus on developing and expanding Pediapharm’s communications with the investment community through a comprehensive investor relations program.
Paradox is an investor relations company founded in 2001 and is based in Montreal, Canada. Paradox provides a wide range of services to companies to help broaden investor exposure and develop a shareholder following.
The term of the agreement entered into between the Corporation and Paradox is for an initial period of six months. In consideration for its services, Pediapharm has agreed to pay to Paradox a monthly fee of $6,800. In addition, the Corporation has granted to Paradox stock options giving it the right to purchase up to 100,000 common shares of the Corporation at an exercise price of $0.36 per common share for a period of one year. The options granted will vest monthly in 12 equal tranches starting on the grant date.
About Pedipharm Inc.
Pediapharm is the only Canadian specialty pharmaceutical company dedicated to serving the needs of the pediatric community. Its mission is to bring to the Canadian market the latest innovative pediatric products with the objective to improve the health and the well-being of children in Canada. Since its debut in 2008, Pediapharm has entered into numerous commercial agreements with partners from Canada and other countries around the world. The company’s innovative product portfolio includes NYDA®; a breakthrough treatment for head lice; EpiCeram® a non-steroid emulsion for eczema; KoolEffect™ which reduces the symptoms of fever; and VapoLyptus™; a soothing vapour patch of Eucalyptus and Camphor.
About Paradox Public Relations Inc.
Paradox Public Relations Inc. was formed in 2001 and is headquartered in Montreal, Quebec, Canada. Its bilingual (English and French) team of professionals offers experience and expertise in investor relations, corporate communications and non-deal road shows. Paradox specializes in the development and marketing of emerging growth, micro cap and small cap companies. With over 13 years of continued service, Paradox has developed extensive national and international contacts including brokers, investment advisors, institutional investors, investment funds, analysts, newsletter writers, media and private investors.
Contact: Pediapharm Inc.
Sylvain Chretien
President and Chief Executive Officer
+1-514-762-2626 ext. 201
sylvain.chretien@pedia-pharm.com
Roland Boivin
Chief Financial Officer
+1-514-762-2626 ext. 202
roland.boivin@pedia-pharm.com
Relations Publiques Paradox Public Relations Inc.
Carl Desjardins
+1-514-341-0408
carldesjardins@paradox-pr.ca
Help employers find you! Check out all the jobs and post your resume.
